TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* participation in the V58P4 study~* mentally competent to understand the nature, the scope and the consequences of the study~* able and willing to give written informed consent prior to study entry~* available for all the visits scheduled in the study~Exclusion Criteria:~* receipt of another investigational agent within 90 days prior to, or before completion of the safety follow-up period in another study, whichever is longer, prior to Visit 7 and unwilling to refuse participation in another clinical study through the end of the present study~* history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine components~* any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or experienced fever (i.e., axillary temperature ≥ 38°C) within the 5 days prior to Visit 7~* pregnant/breast feeding women, or women of childbearing potential who refuse to use a reliable contraceptive method during the three weeks after vaccination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- cTIV (Type: EXPERIMENTAL): Cell culture derived seasonal trivalent influenza vaccine (cTIV)
- eTIV_a (Type: ACTIVE_COMPARATOR): Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
- FLU (cTIV or eTIV_a) (Type: EXPERIMENTAL): Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
- FLU (cTIV or eTIV_a) + PV (Type: ACTIVE_COMPARATOR): 23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed and histologically confirmed glioblastoma multiforme~* Tumor must be surgically accessible and tissue must be available~* Age ≥ 20 years and \< 75 years~* Life expectancy ≥ 6 months~* Baseline MRI images must be done within 2 days after surgery~* Patients must have a Karnofsky performances score ≥ 60 prior to treatment.~* Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors.~* Adequate hematologic (absolute neutrophil count (ANC) ≥ 1.5x109/L, platelet count ≥ 100x109/L, hemoglobin ≥ 10 g/dL ), renal (creatinine ≤ 1.25xULN ), and hepatic function (total bilirubin ≤ 1.5xULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5xULN)~* Women with childbearing potential must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug.~* Both men and women of reproductive potential agree to use approved contraception, such as condom and placement of an intrauterine device (IUD), during the study and until 3 months after the discontinuation of study treatment.~* Willing and able to comply with the protocol as judged by the investigator~* Patients must provide written consent~Exclusion Criteria:~* Any prior chemotherapy (including carmustine-containing wafers) or immunotherapy (including vaccine therapy )~* Any prior radiotherapy to the brain~* Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial~* Any contraindication to TMZ listed in the local label~* Low-grade astrocytoma~* Unable to undergo MRI~* Past medical history of disease with poor prognosis according to the judgment of the Investigator~* HIV infection~* Patients with positive anti-HCV~* Patients with positive HbsAG who received any related treatment within the past 6 months~* Patients suffering from hereditary fructose intolerance (HFI).~* Patients receive any investigational agent(s) or device(s) within 30 days prior to entering the study~* Known coronary artery disease, significant arrhythmias or severe congestive heart failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CAN008 (Type: EXPERIMENTAL): CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Per the current approved labeling for the Conformity European (CE) Marked MitraClip System.~Exclusion Criteria:~* Per the current approved labeling for the CE Marked MitraClip System.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MitraClip Therapy (Type: None): Patients treated with the MitraClip System.
- Medical Management (Type: None): Patients with MR managed non-surgically based on standard hospital clinical practice.
- Mitral Valve Surgery (Type: None): Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women who delivers in the obstetric intent to breast-feed.~* Eligible participants should have been planning of birth spacing~Exclusion Criteria:~* Women refusal to participate in the study~* Women planned to use a method of contraception other than LAM~* Anticipation of difficulty of subsequent communication with the woman

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Counseling for LAM (Type: ACTIVE_COMPARATOR): Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires.
- Counseling for LAM+ LNG-EC (Type: EXPERIMENTAL): LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent obtained before any trial-related activities~* Type 1 diabetes diagnosed and classified according to aetiology~* Duration of type 1 diabetes equal to or more than 12 months~* Glycosylated haemoglobin less than or equal to 12 percent based on analysis from central laboratory~* Able and willing to perform self-blood glucose monitoring~Exclusion Criteria:~* Proliferative retinopathy~* Total basal insulin dose of more than 100 IU per day~* Recurrent major hypoglycaemia - that would interfere with trial participation (as judged by the investigator)~* Known unawareness of hypoglycaemia~* Previous treatment with insulin detemir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin detemir (Type: EXPERIMENTAL): None
- NPH insulin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Bilateral nasal polyps~* Fulfill criteria for polypectomy (be indicated for surgical - FESS - treatment)~Exclusion Criteria:~* Polypectomy within the last 6 months~* Unhealed nasal surgery/trauma~* \>5 previous polypectomies~* Female of childbearing age who is pregnant, lactating, or not using active contraceptive methods~* Nasal infection~* Pulmonary tuberculosis~* Cystic fibrosis, glaucoma, clinically significant cardiovascular, pulmonary, renal, hepatic, metabolic, hematological, or neurological disease~* Immunocompromised~* Rhinitis medicamentosa (rebound congestion following misuse of nasal decongestants)~* Known hereditary mucociliary dysfunction~* Significant nasal structure abnormalities~* Asthmatic attack within the past 30 days~* Asthmatic patients requiring \>1000 mcg beclomethasone or equivalent~* Asthmatic patients not stable on corticosteroid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate Nasal Spray (MFNS) (Type: EXPERIMENTAL): MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
- Placebo (Type: PLACEBO_COMPARATOR): Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* diagnosis of idiopathic Restless Legs Syndrome, confirmed by a score of at least 11 on the RLS Diagnostic Index~* certain severity of symptoms (at least score of 15 on the International Restless Legs Score (IRLS)~* Have had RLS symptoms for at least 15 nights in the last four weeks.~* \< 6 hours of sleep in nights with RLS symptoms~* MADRS (depression rating scale) score of at least 12 (= borderline to depression) at baseline~Exclusion criteria:~* any other sleep disorder that might interfere with the RLS symptoms or sleep (e.g. sleep apnea disorder, narcolepsy)~* Secondary RLS due to diagnosis of renal insufficiency, polyneuropathy, pregnancy (see below), iron deficiency anemia~* Any significant psychiatric disorders (e.g. schizophrenia, bipolar disorder); depression which by judgement of the investigator is caused by RLS, is not an exclusion criterion.~* Current or past suicidality~* medication known to trigger/aggravate/ cause or interfere with RLS symptoms (e.g. most antidepressants, lithium, neuroleptics, opioids, carbidopa, clonidine, antihistamines, anticonvulsants etc.).~* daytime RLS symptoms which require treatment (daytime: 10 a.m. until 6 p.m.).~* concomitant movement disorders (e.g. Parkinson's Disease, dyskinesia, dystonia).~* medical conditions with symptoms which could affect assessments of efficacy (e.g. diabetes, rheumatoid arthritis, fibromyalgia syndrome, cancer etc.).~* Subjects taking any medication known to induce drowsiness or to affect sleep.~* Subjects who are pregnant, lactating or of childbearing potential. Women of childbearing potential must use adequate contraception~* clinically significant or unstable medical conditions (e.g. severe heart disease, severe liver or kidney disease etc.).~* pain syndromes, caused by other disorders than RLS~* excessive caffeine intake~* diastolic blood pressure \>110mmHg or \<50mmHg or systolic blood pressure \>180mmHg or \<90mmHg at baseline.~* Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) or the oral contraceptive pill (OCP) and/or certain drugs which are known to interact with ropinirole (e.g. ciprofloxacin, cimetidine, tobacco, omeprazole).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy ambulatory postmenopausal (≥ 5 years) women from 50 to 85 years of age (inclusive) with a diagnosis of osteoporosis~* The women are to have a bone mineral density (BMD) T score ≤ -2.5 and \> -5.0 at the lumbar spine or hip (femoral neck) by dual energy x-ray absorptiometry (DXA) and radiological evidence of 2 or more mild or one or more moderate lumbar or thoracic vertebral fractures, or history of low trauma forearm, humerus, sacral, pelvic, hip, femoral, or tibial fracture within the past 5 years. Postmenopausal women older than 65 who meet the above fracture criteria but have a T score ≤ -2.0 and \> -5.0 may be enrolled. Women older than 65 who do not meet the fracture criteria may also be enrolled if their T score is ≤ -3.0 and \> -5.0~* Normal physical exam, vital signs, electrocardiogram (ECG) and medical history~* Laboratory tests within the normal range including serum calcium, PTH(1-84), serum phosphorus and alkaline phosphatase~Exclusion Criteria:~* History of more than 4 mild or moderate spine fractures or any severe fracture~* Abnormality of the spine or hip that would prohibit assessment of bone mineral density (BMD)~* Unexplained elevation of serum alkaline phosphatase, history of bone disorders (such as Paget's disease) or a diagnosis of cancer within the last 5 years (with the exception of basal cell or squamous cancer of the skin)~* History of thyroid, parathyroid, or adrenal disorders, or malabsorptive syndromes or any chronic or recurrent diseases or disturbances that would interfere with the interpretation of study data or compromise the safety of the patient~* Prior treatment with parathyroid hormone (PTH) or parathyroid hormone-related peptid (PTHrP)~* Prior treatment with bisphosphonates, fluoride, or strontium within the past five years or treatment with androgens, anabolic steroids, corticosteroids or selective estrogen receptor modulators within the past 12 months (except hormone replacement therapy)~* Prior treatment with an investigational drug within the past 12 months~* History of nephrolithiasis or urolithiasis within the past five years, or history of osteosarcoma at any time

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo identical in appearance to BA058 study drug
- BA058 80 mcg (abaloparatide) (Type: EXPERIMENTAL): None
- teriparatide (Type: ACTIVE_COMPARATOR): Blinded until after randomization, then open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Ambulatory, postmenopausal Japanese women with osteoporosis (defined as bone mineral density T-score of ≤ -4.00 at the lumbar spine or BMD T-score of ≤ -3.50 at the total hip, or femoral neck)~Exclusion Criteria:~* Severe osteoporosis~* Use of agents affecting bone metabolism~* History of metabolic or bone disease (except osteoporosis)~* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)~* Current hyper- or hypocalcemia~* Current, uncontrolled hyper- or hypothyroidism~* Current, uncontrolled hyper- or hypoparathyroidism

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
- Romosozumab 70 mg (Type: EXPERIMENTAL): Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Romosozumab 140 mg (Type: EXPERIMENTAL): Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Romosozumab 210 mg (Type: EXPERIMENTAL): Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maximizing Trichiasis Surgery Success

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least one eyelid with previously unoperated upper eyelid trichiasis~* Willing to comply with all study procedures and be available for the duration of the study~Exclusion Criteria:~* Inability to provide independent, informed consent~* All eyes with previously unoperated trichiasis are phthisical

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bilamellar 3 mm (Type: ACTIVE_COMPARATOR): Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
- Bilamellar 5mm (Type: ACTIVE_COMPARATOR): Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
- Trabut 3mm (Type: ACTIVE_COMPARATOR): Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of AML in the status of primary induction failure (i.e. persistent leukemia after 2 courses of induction chemotherapy or persisting bone marrow hypoplasia fol-lowing induction chemotherapy +/-minimal residual disease)~* Age: 18-55 years~* Availability of an HLA identical family donor OR unrelated donor with matching in 10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of 1 allele or antigen mismatch OR family donor with maximum 1 allele mismatch.~* Have adequate renal and hepatic functions as indicated by the following laboratory values:~* Serum creatinine ≤1.0 mg/dL; if serum creatinine \>1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \>60 mL/min/1.73 m² as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female)~* Serum bilirubin ≤1.5 mg/dL × upper limit of normal (ULN)~* Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 × ULN~* Alkaline phosphatase ≤2.5 × ULN~Exclusion Criteria:~* Documented chloroma~* Patients having AML M3~* Documented leukemic infiltration of CNS/cerebrospinal fluid~* Karnofsky performance score below \< 60%~* Acute or chronic heart failure~* HIV infection, chronic viral hepatitis~* Severe neurological or psychiatric disorders~* Any circumstances that preclude the use of the drugs used within the protocol~* Prior allogeneic or autologous stem cell transplantation~* \> 3 courses of prior chemotherapy~* Denied informed consent~* Pregnancy or denied of effective contraceptive method

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete